Selective Inhibition of HDAC6 Promotes Bladder Cancer Radiosensitization and Mitigates the Radiation-induced CXCL1 Signalling

Overview

Journal Br J Cancer

Specialty Oncology

Date 2023 Feb 22

PMID 36810912

Authors

Yu-Chieh Tsai

Tzu-Yin Wang

Chia-Lang Hsu

Wei-Chou Lin

Jyun-Yu Chen

Jia-Hua Li

Yeong-Shiau Pu

Ann-Lii Cheng

Jason Chia-Hsien Cheng

Sheng-Fang Su

Affiliations

Soon will be listed here.

Abstract

Background: Although trimodality therapy resecting tumours followed by chemoradiotherapy is emerged for muscle-invasive bladder cancer (MIBC), chemotherapy produces toxicities. Histone deacetylase inhibitors have been identified as an effective strategy to enhance cancer radiotherapy (RT).

Methods: We examined the role of HDAC6 and specific inhibition of HDAC6 on BC radiosensitivity by performing transcriptomic analysis and mechanism study.

Results: HDAC6 knockdown or HDAC6 inhibitor (HDAC6i) tubacin exerted a radiosensitizing effect, including decreased clonogenic survival, increased H3K9ac and α-tubulin acetylation, and accumulated γH2AX, which are similar to the effect of panobinostat, a pan-HDACi, on irradiated BC cells. Transcriptomics of shHDAC6-transduced T24 under irradiation showed that shHDAC6 counteracted RT-induced mRNA expression of CXCL1, SERPINE1, SDC1 and SDC2, which are linked to cell migration, angiogenesis and metastasis. Moreover, tubacin significantly suppressed RT-induced CXCL1 and radiation-enhanced invasion/migration, whereas panobinostat elevated RT-induced CXCL1 expression and invasion/migration abilities. This phenotype was significantly abrogated by anti-CXCL1 antibody, indicating the key regulator of CXCL1 contributing to BC malignancy. Immunohistochemical evaluation of tumours from urothelial carcinoma patients supported the correlation between high CXCL1 expression and reduced survival.

Conclusion: Unlike pan-HDACi, the selective HDAC6i can enhance BC radiosensitization and effectively inhibit RT-induced oncogenic CXCL1-Snail-signalling, thus further advancing its therapeutic potential with RT.

Citing Articles

Molecular mechanisms of m6A modifications regulating tumor radioresistance.

Shen R, Jiang Z, Wang H, Zheng Z, Jiang X Mol Med. 2025; 31(1):64.

PMID: 39972266 PMC: 11837317. DOI: 10.1186/s10020-025-01121-9.

Effects of a novel HDAC6-selective inhibitor's radiosensitization on cancer cells.

Hu H, Wang Q, Zhang Y, Yang S, Shen A, Yan J Mol Biol Rep. 2024; 51(1):1151.

PMID: 39537948 DOI: 10.1007/s11033-024-10084-9.

Stress granules in cancer: Adaptive dynamics and therapeutic implications.

Jia Y, Jia R, Dai Z, Zhou J, Ruan J, Chng W iScience. 2024; 27(8):110359.

PMID: 39100690 PMC: 11295550. DOI: 10.1016/j.isci.2024.110359.

Selective HDAC6 Inhibition Has the Potential for Anti-Cancer Effect in Renal Cell Carcinoma.

Anraku T, Murata M, Kuroki H, Kazama A, Shirono Y, Tasaki M J Pers Med. 2024; 14(7).

PMID: 39063958 PMC: 11278056. DOI: 10.3390/jpm14070704.

The Clinical Significance and Involvement in Molecular Cancer Processes of Chemokine CXCL1 in Selected Tumors.

Korbecki J, Bosiacki M, Szatkowska I, Kupnicka P, Chlubek D, Baranowska-Bosiacka I Int J Mol Sci. 2024; 25(8).

PMID: 38673949 PMC: 11050300. DOI: 10.3390/ijms25084365.

References

Pan C, Yang X, Lopez-Beltran A, MacLennan G, Eble J, Koch M . c-kit Expression in small cell carcinoma of the urinary bladder: prognostic and therapeutic implications. Mod Pathol. 2004; 18(3):320-3. DOI: 10.1038/modpathol.3800318. View

Ree A, Dueland S, Folkvord S, Hole K, Seierstad T, Johansen M . Vorinostat, a histone deacetylase inhibitor, combined with pelvic palliative radiotherapy for gastrointestinal carcinoma: the Pelvic Radiation and Vorinostat (PRAVO) phase 1 study. Lancet Oncol. 2010; 11(5):459-64. DOI: 10.1016/S1470-2045(10)70058-9. View

Merico D, Isserlin R, Stueker O, Emili A, Bader G . Enrichment map: a network-based method for gene-set enrichment visualization and interpretation. PLoS One. 2010; 5(11):e13984. PMC: 2981572. DOI: 10.1371/journal.pone.0013984. View

Putcha P, Yu J, Rodriguez-Barrueco R, Saucedo-Cuevas L, Villagrasa P, Murga-Penas E . HDAC6 activity is a non-oncogene addiction hub for inflammatory breast cancers. Breast Cancer Res. 2015; 17(1):149. PMC: 4672555. DOI: 10.1186/s13058-015-0658-0. View

Groselj B, Sharma N, Hamdy F, Kerr M, Kiltie A . Histone deacetylase inhibitors as radiosensitisers: effects on DNA damage signalling and repair. Br J Cancer. 2013; 108(4):748-54. PMC: 3590661. DOI: 10.1038/bjc.2013.21. View

Kim I, No M, Lee J, Shin J, Oh J, Choi E . Epigenetic modulation of radiation response in human cancer cells with activated EGFR or HER-2 signaling: potential role of histone deacetylase 6. Radiother Oncol. 2009; 92(1):125-32. DOI: 10.1016/j.radonc.2009.03.008. View

Hubbert C, Guardiola A, Shao R, Kawaguchi Y, Ito A, Nixon A . HDAC6 is a microtubule-associated deacetylase. Nature. 2002; 417(6887):455-8. DOI: 10.1038/417455a. View

Lenis A, Lec P, Chamie K, Mshs M . Bladder Cancer: A Review. JAMA. 2020; 324(19):1980-1991. DOI: 10.1001/jama.2020.17598. View

Miyake M, Lawton A, Goodison S, Urquidi V, Gomes-Giacoia E, Zhang G . Chemokine (C-X-C) ligand 1 (CXCL1) protein expression is increased in aggressive bladder cancers. BMC Cancer. 2013; 13:322. PMC: 3708804. DOI: 10.1186/1471-2407-13-322. View

10.

Gomes-Giacoia E, Miyake M, Goodison S, Rosser C . Targeting plasminogen activator inhibitor-1 inhibits angiogenesis and tumor growth in a human cancer xenograft model. Mol Cancer Ther. 2013; 12(12):2697-708. PMC: 4317369. DOI: 10.1158/1535-7163.MCT-13-0500. View

11.

Takhar H, Singhal N, Gowda R, Penniment M, Takhar P, Brown M . Phase I study evaluating the safety and efficacy of oral panobinostat in combination with radiotherapy or chemoradiotherapy in patients with inoperable stage III non-small-cell lung cancer. Anticancer Drugs. 2015; 26(10):1069-77. DOI: 10.1097/CAD.0000000000000282. View

12.

Zuo Q, Wu W, Li X, Zhao L, Chen W . HDAC6 and SIRT2 promote bladder cancer cell migration and invasion by targeting cortactin. Oncol Rep. 2011; 27(3):819-24. DOI: 10.3892/or.2011.1553. View

13.

Groselj B, Ruan J, Scott H, Gorrill J, Nicholson J, Kelly J . Radiosensitization by Histone Deacetylase Inhibition with No Increase in Early Normal Tissue Radiation Toxicity. Mol Cancer Ther. 2017; 17(2):381-392. PMC: 5712223. DOI: 10.1158/1535-7163.MCT-17-0011. View

14.

Camphausen K, Tofilon P . Inhibition of histone deacetylation: a strategy for tumor radiosensitization. J Clin Oncol. 2007; 25(26):4051-6. DOI: 10.1200/JCO.2007.11.6202. View

15.

Liao Y, Smyth G, Shi W . featureCounts: an efficient general purpose program for assigning sequence reads to genomic features. Bioinformatics. 2013; 30(7):923-30. DOI: 10.1093/bioinformatics/btt656. View

16.

Namdar M, Perez G, Ngo L, Marks P . Selective inhibition of histone deacetylase 6 (HDAC6) induces DNA damage and sensitizes transformed cells to anticancer agents. Proc Natl Acad Sci U S A. 2010; 107(46):20003-8. PMC: 2993347. DOI: 10.1073/pnas.1013754107. View

17.

Pulya S, Amin S, Adhikari N, Biswas S, Jha T, Ghosh B . HDAC6 as privileged target in drug discovery: A perspective. Pharmacol Res. 2020; 163:105274. DOI: 10.1016/j.phrs.2020.105274. View

18.

Paillas S, Then C, Kilgas S, Ruan J, Thompson J, Elliott A . The Histone Deacetylase Inhibitor Romidepsin Spares Normal Tissues While Acting as an Effective Radiosensitizer in Bladder Tumors in Vivo. Int J Radiat Oncol Biol Phys. 2020; 107(1):212-221. PMC: 7181176. DOI: 10.1016/j.ijrobp.2020.01.015. View

19.

Nakashima M, Matsui Y, Kobayashi T, Saito R, Hatahira S, Kawakami K . Urine CXCL1 as a biomarker for tumor detection and outcome prediction in bladder cancer. Cancer Biomark. 2015; 15(4):357-64. DOI: 10.3233/CBM-150472. View

20.

Adeegbe D, Liu Y, Lizotte P, Kamihara Y, Aref A, Almonte C . Synergistic Immunostimulatory Effects and Therapeutic Benefit of Combined Histone Deacetylase and Bromodomain Inhibition in Non-Small Cell Lung Cancer. Cancer Discov. 2017; 7(8):852-867. PMC: 5540748. DOI: 10.1158/2159-8290.CD-16-1020. View